Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: A report from the children’s oncology group

  • Douglas S. Hawkins
  • , Yueh Yun Chi
  • , James R. Anderson
  • , Jing Tian
  • , Carola A.S. Arndt
  • , Lisa Bomgaars
  • , Sarah S. Donaldson
  • , Andrea Hayes-Jordan
  • , Leo Mascarenhas
  • , Mary Beth Mccarville
  • , Jeannine S. Mccune
  • , Geoff Mccowage
  • , Lynn Million
  • , Carol D. Morris
  • , David M. Parham
  • , David A. Rodeberg
  • , Erin R. Rudzinski
  • , Margarett Shnorhavorian
  • , Sheri L. Spunt
  • , Stephen X. Skapek
    • Lisa A. Teot, Suzanne Wolden, Torunn I. Yock, William H. Meyer

Producción científica: Article › revisión exhaustiva

164 Citas (Scopus)

Huella

Profundice en los temas de investigación de 'Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: A report from the children’s oncology group'. En conjunto forman una huella única.

Pharmacology, Toxicology and Pharmaceutical Science